Skip to main content

Table 1 Baseline demographic data

From: Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy

No. of eyes (n)

22

 PNV eyes

14

  Right / Left

8 / 6

 Partner eyes

8

  Right / Left

3 / 5

No. of patients (n)

11

Gender (m/f)

7/4

Mean age (years)

64.2 ± 4.0 (range: 60–72)

Mean follow-up (y)

1.8 ± 0.4 (1.00–2.00)

 Year 1

22 (100%)

 Year 2

17 (77.2%)

Pachychoroid disease stage

 PNV eyes (n = 14)

  1 (PPE)

0

  2 (CSC)

0

  3 (PNV)

14 (100%)

  4 (PAT1)

0

 Partner eyes (n = 8)

  1 (PPE)

4 (50%)

  2 (CSC)

1 (12.5%)

  3 (PNV)

0

  4 (PAT1)

0

Macular morphology

 PNV eyes

  Subretinal fluid

14 (100%)

  Intraretinal fluid

0

  Flat, irregular PED

14 (100%)

  CNV

14 (100%)

 Partner eyes

  Subretinal fluid

1

  Intraretinal fluid

0

  Flat, irregular PED

0

  CNV

0

Mean Ranibizumab injections

 PNV eyes

  Year 1

7.0 ± 2.9 (2–11)

  Year 2

6.5 ± 3.1 (1–10)

 Partner Eyes

  Year 1

0

  Year 2

0